PAM
AXN

Panagora Asset Management’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Panagora Asset Management’s Portfolio AXN Stock Details AXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-49,068
Closed -$20K – 2719
2017
Q1 		$20K Buy
49,068
+25,431
+108% +$10.9K ﹤0.01% 2184
2016
Q4 		$8K Hold
23,637
– – ﹤0.01% 2296
2016
Q3 		$13K Buy
+23,637
New +$15.9K ﹤0.01% 2319

Other funds holding AXN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Panagora Asset Management's AXN Position: Q2 2017 in Review

Panagora Asset Management sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q2 2017, closing a stake of 49,068 shares — an estimated $20K sold.

Panagora Asset Management first reported a position in AXN in Q3 2016 and held it in 3 quarters. The position peaked at $20K in Q1 2017. 7 funds tracked by Wall St. Rank hold AXN as of Q2 2017.

  • Panagora Asset Management reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q2 2017 after selling out during the quarter.
  • Panagora Asset Management sold 49,068 Aoxing Pharmaceutical Company Inc. shares in Q2 2017, an estimated $20K.
  • Panagora Asset Management first reported a position in Aoxing Pharmaceutical Company Inc. in Q3 2016 and held it in 3 quarters.
  • Panagora Asset Management's Aoxing Pharmaceutical Company Inc. position peaked at $20K in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q2 2017.

Based on Panagora Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.